Oneness Biotech founder Kong Ming Lu revealed yesterday (28) that the company plans to acquire a pharmaceutical company in the United States. The acquisition will be executed by its affiliated company, Diamond BioFund, which holds at least $200 million (approximately NT$6.5 billion) in funds. The focus is on acquiring a U.S.-based wound care company, with the goal of securing not only independent distribution channels but ideally also self-owned production lines.
During an online earnings call held by Oneness Biotech, Kong Ming Lu shared these details. He emphasized that the company’s diabetic foot ulcer product "Fespixon" (ON101) has obtained market approval in 60 countries globally, with the U.S. market launch being the most important development this year.
In addition to actively negotiating partnerships with various U.S. companies, Oneness Biotech is also evaluating the acquisition of a U.S. company to gain production lines and sales channels for wound care.
When asked why the company is planning an acquisition in the U.S., Kong Ming Lu explained that following U.S. President Trump’s tariff policies, the U.S. capital markets have declined, making this an ideal time to look for acquisition targets and "pick up bargains."
Oneness Biotech's Chief Academic Officer, Jui-Ching Chen, reported that "Fespixon" has completed a 170-patient post-market "real-world study" in Taiwan, with 80% of wounds showing healing after 120 days, and a 76% healing rate for infected ulcers.
Kong Ming Lu further explained that, outside of Taiwan, six countries have applied for drug approval for "Fespixon" under the new drug name Fespixon, with the Chinese market planning to submit a medical insurance application after reducing the dosage later this year. Currently, the product is being marketed through the authorized partner China Resources Sanjiu Pharmaceutical, and five major leading hospitals are spearheading the establishment of 100 wound care centers.
In markets like the U.S. and 23 other countries, the product is being marketed as a medical device under the name Bonvadis. Bonvadis has already developed eight different indications for medical device approvals. In April of this year, the company applied to the U.S. Food and Drug Administration (FDA) for approval of Bonvadis for all wound indications. Initially, Oneness Biotech had planned to wait for approval of the full wound indication before fully promoting the product in the U.S. However, the company will now adopt a more flexible approach, launching the product based on individual indications.
Kong Ming Lu explained that to expedite the global market entry of "Fespixon," the company will adopt flexible marketing strategies for multi-indication products. This approach will expand the product from being limited to diabetic foot ulcers to include eight different indications, with separate packaging and pricing for each. The company may even collaborate with large pharmaceutical companies as an OEM partner, transforming the product into a dynamic market presence.
Resource: 合一撿便宜要併美國藥廠 順勢銷售新藥「速必一」
